T1	p 94 116	diarrhea in children .
T2	p 190 200	children .
T3	p 726 748	infants and children .
T4	p 770 959	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency
T5	p 1462 1500	patients : 73 ( 57 % ) Shigella ; 23 (
T6	p 2434 2462	pediatric patients requiring
T7	i 6 54	Oral ciprofloxacin vs. intramuscular ceftriaxone
T8	i 281 320	antibiotics , intramuscular ceftriaxone
T9	i 665 678	ciprofloxacin
T10	i 999 1023	ciprofloxacin suspension
T11	i 1043 1061	day + im placebo ;
T12	i 1071 1124	or im ceftriaxone ( 50 mg/kg/day + placebo suspension
T13	i 1803 1816	ciprofloxacin
T14	i 1821 1832	ceftriaxone
T15	i 2138 2149	ceftriaxone
T16	i 2298 2311	ciprofloxacin
T17	i 2355 2366	ceftriaxone
T18	o 79 102	acute invasive diarrhea
T19	o 227 258	resistance of enteric pathogens
T20	o 614 633	efficacy and safety
T21	o 714 722	diarrhea
T22	o 1325 1353	Clinical response and safety
T23	o 1421 1443	isolated 127 pathogens
T24	o 1575 1608	Overall bacteriologic eradication
T25	o 1738 1766	Clinical cure or improvement
T26	o 1857 1883	Serum ciprofloxacin values
T27	o 2056 2083	drug-related adverse events
T28	o 2396 2419	acute invasive diarrhea